Cardiac troponin elevation and mortality in takotsubo syndrome: New insights from the international takotsubo registry.
myocardial injury
risk prediction
takotsubo syndrome
troponin
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
13 Oct 2024
13 Oct 2024
Historique:
received:
03
01
2024
accepted:
25
05
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
14
10
2024
Statut:
aheadofprint
Résumé
The clinical relevance of cardiac troponin (cTn) elevation in takotsubo syndrome (TTS) remains uncertain. The present study sought to investigate the role of cardiac troponin (cTn) elevations in mortality prediction of patients with Takotsubo syndrome (TTS). Patients enrolled in the International Takotsubo (InterTAK) Registry from January 2011 to February 2020 with available data on peak cTn levels were included in the analysis. Peak cTn levels during the index hospitalization were used to define clinically relevant myocardial injury. The threshold at which clinically relevant myocardial injury drives mortality at 1 year was identified using restricted cubic spline analysis. Out of 2'938 patients, 222 (7.6%) patients died during 1-year follow-up. A more than 28.8-fold increase of cTn above the upper reference limit was identified as threshold for clinically relevant myocardial injury. The presence of clinically relevant myocardial injury was significantly associated with an increased risk of mortality at 5 years (adjusted HR 1.58, 95% CI 1.18-2.12, p =.002). Clinically relevant myocardial injury was related to an increased 5-year mortality risk in patients with apical TTS (adjusted HR 1.57, 95% CI 1.21-2.03, p =.001), in presence of physical stressors (adjusted HR 1.60, 95% CI 1.22-2.11, p =.001), and in absence of emotional stressors (adjusted HR 1.49, 95% CI, 1.17-1.89, p =.001). This study for the first time determined a troponin threshold for the identification of TTS patients at excess risk of mortality. These findings advance risk stratification in TTS and assist in identifying patients in need for close monitoring and follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
The clinical relevance of cardiac troponin (cTn) elevation in takotsubo syndrome (TTS) remains uncertain. The present study sought to investigate the role of cardiac troponin (cTn) elevations in mortality prediction of patients with Takotsubo syndrome (TTS).
METHODS
METHODS
Patients enrolled in the International Takotsubo (InterTAK) Registry from January 2011 to February 2020 with available data on peak cTn levels were included in the analysis. Peak cTn levels during the index hospitalization were used to define clinically relevant myocardial injury. The threshold at which clinically relevant myocardial injury drives mortality at 1 year was identified using restricted cubic spline analysis.
RESULTS
RESULTS
Out of 2'938 patients, 222 (7.6%) patients died during 1-year follow-up. A more than 28.8-fold increase of cTn above the upper reference limit was identified as threshold for clinically relevant myocardial injury. The presence of clinically relevant myocardial injury was significantly associated with an increased risk of mortality at 5 years (adjusted HR 1.58, 95% CI 1.18-2.12, p =.002). Clinically relevant myocardial injury was related to an increased 5-year mortality risk in patients with apical TTS (adjusted HR 1.57, 95% CI 1.21-2.03, p =.001), in presence of physical stressors (adjusted HR 1.60, 95% CI 1.22-2.11, p =.001), and in absence of emotional stressors (adjusted HR 1.49, 95% CI, 1.17-1.89, p =.001).
CONCLUSION
CONCLUSIONS
This study for the first time determined a troponin threshold for the identification of TTS patients at excess risk of mortality. These findings advance risk stratification in TTS and assist in identifying patients in need for close monitoring and follow-up.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14317Subventions
Organisme : Abbott Vascular
Organisme : Biotronik
Organisme : Iten-Kohaut Foundation
ID : NA
Organisme : Medtronic Foundation
Organisme : MicroPort
Organisme : SMT
Organisme : Deutsches Zentrum für Herz-Kreislaufforschung
ID : NA
Organisme : Biss Davies Charitable Trust
Organisme : Edwards Lifesciences
Organisme : Schnell Medical
Organisme : Boston Scientific Corporation
Organisme : swiss national foundation
ID : NA
Informations de copyright
© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J. 2018;39:2032‐2046.
Ghadri JR, Ruschitzka F, Luscher TF, Templin C. Takotsubo cardiomyopathy: still much more to learn. Heart. 2014;100:1804‐1812.
Kato K, Lyon AR, Ghadri JR, Templin C. Takotsubo syndrome: aetiology, presentation and treatment. Heart. 2017;103:1461‐1469.
Rozema T, Klein LR. Takotsubo cardiomyopathy: a case report and literature review. Cardiol Young. 2016;26:406‐409.
Chinali M, Formigari R, Grutter G. Takotsubo cardiomyopathy in a young adult with transplanted heart: what happened to denervation? ESC Heart Fail. 2018;5:197‐200.
Ghadri JR, Cammann VL, Napp LC, et al. Differences in the clinical profile and outcomes of typical and atypical takotsubo syndrome: data from the international takotsubo registry. JAMA Cardiol. 2016;1:335‐340.
Wischnewsky MB, Candreva A, Bacchi B, et al. Prediction of short‐ and long‐term mortality in takotsubo syndrome: the InterTAK prognostic score. Eur J Heart Fail. 2019;21:1469‐1472.
Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation. Eur Heart J. 2021;42:1289‐1367.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138:e618‐e651.
Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929‐938.
Rodes‐Cabau J, Gutierrez M, Bagur R, et al. Incidence, predictive factors, and prognostic value of myocardial injury following uncomplicated transcatheter aortic valve implantation. J Am Coll Cardiol. 2011;57:1988‐1999.
Barbash IM, Dvir D, Ben‐Dor I, et al. Prevalence and effect of myocardial injury after transcatheter aortic valve replacement. Am J Cardiol. 2013;111:1337‐1343.
Yong ZY, Wiegerinck EM, Boerlage‐van Dijk K, et al. Predictors and prognostic value of myocardial injury during transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2012;5:415‐423.
Stahli BE, Yonekawa K, Altwegg LA, et al. Clinical criteria replenish high‐sensitive troponin and inflammatory markers in the stratification of patients with suspected acute coronary syndrome. PLoS One. 2014;9:e98626.
Schindler M, Stockli F, Brutsch R, et al. Postprocedural troponin elevation and mortality after transcatheter aortic valve implantation. J Am Heart Assoc. 2021;10:e020739.
Goliasch G, Winter MP, Ayoub M, et al. A contemporary definition of periprocedural myocardial injury after percutaneous coronary intervention of chronic Total occlusions. JACC Cardiovasc Interv. 2019;12:1915‐1923.
Toma A, Stahli BE, Gebhard C, et al. Clinical implications of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention for chronic total occlusion: role of antegrade and retrograde crossing techniques. EuroIntervention. 2018;13:2051‐2059.
Ghadri JR, Kato K, Cammann VL, et al. Long‐term prognosis of patients with takotsubo syndrome. J Am Coll Cardiol. 2018;72:874‐882.
Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on takotsubo syndrome (part II): diagnostic workup, outcome, and management. Eur Heart J. 2018;39:2047‐2062.
Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352:539‐548.
Templin C, Napp LC, Ghadri JR. Takotsubo syndrome: underdiagnosed, underestimated, but understood? J Am Coll Cardiol. 2016;67:1937‐1940.
Schneider B, Athanasiadis A, Stollberger C, et al. Gender differences in the manifestation of tako‐tsubo cardiomyopathy. Int J Cardiol. 2013;166:584‐588.
Omerovic E, Citro R, Bossone E, et al. Pathophysiology of takotsubo syndrome ‐ a joint scientific statement from the heart failure association takotsubo syndrome study group and myocardial function working Group of the European Society of cardiology ‐ part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. Eur J Heart Fail. 2022;24(2):257‐273.
Lyon AR, Citro R, Schneider B, et al. Pathophysiology of takotsubo syndrome: JACC state‐of‐the‐art review. J Am Coll Cardiol. 2021;77:902‐921.
Heather LC, Catchpole AF, Stuckey DJ, Cole MA, Carr CA, Clarke K. Isoproterenol induces in vivo functional and metabolic abnormalities: similar to those found in the infarcted rat heart. J Physiol Pharmacol. 2009;60:31‐39.
Templin C, Manka R, Cammann VL, et al. Takotsubo syndrome in coronavirus disease 2019. Am J Cardiol. 2021;138:118‐120.